IONIS PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 29, 2026
IONS$28.19-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Description | Shares | Amount | Paid in Capital | Comprehensive Loss | Accumulated Deficit | Stockholders' Equity |
| Balance at March 31, 2025 | 159,041 | $159 | $2,901,262 | $(28,949) | $(2,396,746) | $475,726 |
| Net income | - | - | - | - | 123,551 | 123,551 |
| Change in unrealized gains, net of tax | - | - | - | 367 | - | 367 |
| Foreign currency translation | - | - | - | 595 | - | 595 |
| Issuance of common stock in connection with employee stock plans, net | 156 | - | 1,286 | - | - | 1,286 |
| Stock-based compensation expense | - | - | 30,199 | - | - | 30,199 |
| Balance at June 30, 2025 | 159,197 | $159 | $2,932,747 | $(27,987) | $(2,273,195) | $631,724 |
| Balance at March 31, 2026 | 165,902 | $166 | $3,245,994 | $(31,023) | $(2,723,723) | $491,414 |
| Net loss | - | - | - | - | (114,646) | (114,646) |
| Change in unrealized losses, net of tax | - | - | - | (2,824) | - | (2,824) |
| Foreign currency translation | - | - | - | (50) | - | (50) |
| Issuance of common stock in connection with employee stock plans, net | 568 | - | 20,258 | - | - | 20,258 |
| Stock-based compensation expense | - | - | 45,595 | - | - | 45,595 |
| Shares issued to settle conversion obligation of 0 percent convertible senior notes due 2026, net | 1,798 | (2) | (13) | - | - | (15) |
| Retirement of shares received from the exercise of bond hedges related to 0 percent convertible senior notes due 2026 | (2,631) | 2 | 3 | - | - | 5 |
| Balance at June 30, 2026 | 165,637 | $166 | $3,311,837 | $(33,897) | $(2,838,369) | $439,737 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Description | Shares | Amount | Paid in Capital | Comprehensive Loss | Accumulated Deficit | Stockholders' Equity |
| Balance at December 31, 2024 | 157,909 | $158 | $2,868,812 | $(30,811) | $(2,249,808) | $588,351 |
| Net loss | - | - | - | - | (23,387) | (23,387) |
| Change in unrealized gains, net of tax | - | - | - | 1,997 | - | 1,997 |
| Foreign currency translation | - | - | - | 827 | - | 827 |
| Issuance of common stock in connection with employee stock plans, net | 1,288 | 1 | 3,527 | - | - | 3,528 |
| Stock-based compensation expense | - | - | 60,408 | - | - | 60,408 |
| Balance at June 30, 2025 | 159,197 | $159 | $2,932,747 | $(27,987) | $(2,273,195) | $631,724 |
| Balance at December 31, 2025 | 163,305 | $163 | $3,145,402 | $(25,281) | $(2,631,195) | $489,089 |
| Net loss | - | - | - | - | (207,174) | (207,174) |
| Change in unrealized losses, net of tax | - | - | - | (8,428) | - | (8,428) |
| Foreign currency translation | - | - | - | (188) | - | (188) |
| Issuance of common stock in connection with employee stock plans, net | 3,165 | 3 | 77,557 | - | - | 77,560 |
| Stock-based compensation expense | - | - | 88,888 | - | - | 88,888 |
| Shares issued to settle conversion obligation of 0 percent convertible senior notes due 2026, net | 1,798 | (2) | (13) | - | - | (15) |
| Retirement of shares received from the exercise of bond hedges related to 0 percent convertible senior notes due 2026 | (2,631) | 2 | 3 | - | - | 5 |
| Balance at June 30, 2026 | 165,637 | $166 | $3,311,837 | $(33,897) | $(2,838,369) | $439,737 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.